AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa and ...
Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. Membership (fee-based) Forbes Technology Council is an invitation-only, fee-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results